Navigation Links
Ferring Pharmaceuticals To Develop Major Corporate Center in Parsippany, New Jersey

PARSIPPANY, N.J., Nov. 21, 2011 /PRNewswire/ -- Switzerland-based Ferring Pharmaceuticals today announced the purchase of a 25-acre site at 100 Interpace Parkway in Parsippany, N.J.  The new facility will house a state-of-the art, expanded U.S. Operations Center. The expansion is expected to generate jobs in the New Jersey area, countering recent trends in the pharmaceutical industry.

The U.S. Operations Center will be a fully integrated pharmaceutical facility that will house management, administration and support, commercial operations, manufacturing and product development.  It will include a state-of-the-art manufacturing suite, next-generation product development laboratories, a fully equipped education and training conference center, and administrative offices.

"As a private company, Ferring has a long term orientation, as well as a commitment to follow the science to benefit patients. This new facility underscores our long-term commitment to the U.S. market, as well as the State of New Jersey," said Aaron Graff, President and Chief Operating Officer of Ferring Pharmaceuticals, Inc. 

"Together with our Global Research Center in San Diego, this symbolizes our focus on accelerating Ferring growth in the United States.  The local community has continuously expressed support for our endeavors, and we are so pleased to expand our operations in an area with such a large base of talented, highly trained pharmaceutical professionals." 

The Switzerland-based company has experienced consistent double-digit growth in the U.S. and has approximately 600 U.S. employees. Globally Ferring has nearly 5,000 employees with operations in more than 45 countries.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, global pharmaceutical company. Ferring Pharmaceuticals offers a line of products in the U.S. market. They include: BRAVELLE® (urofollitropin for injection, purified), MENOPUR® (menotropins for injection, USP) and REPRONEX® (menotropins for injection, USP), NOVAREL® (chorionic gonadotropin for injection, USP), ENDOMETRIN® (progesterone) Vaginal Insert, LYSTEDA® (tranexamic acid tablets), FIRMAGON® (degarelix for injection), and EUFLEXXA® (1% sodium hyaluronate).

Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopaedics and urology. For more information, call 1-888-FERRING (1-888-337-7464) or visit

All registered trademarks above are owned by Ferring B.V.


SOURCE Ferring Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ferring Pharmaceuticals Inc. Congratulates All 2011 Summer National Senior Games Athletes
2. Ferring Pharmaceuticals to Support Great Prostate Cancer Challenge® Events Across the Country in National Effort to End Prostate Cancer
3. Ferring Celebrates Winners of 2010 My Little Miracle Essay Contest During National Infertility Awareness Week
4. Ferring Pharmaceuticals, Inc. Congratulates R&B and Pop Icon Gloria Gaynor, Named Woman of the Year by Arthritis Foundation
5. Ferring Pharmaceuticals FIRMAGON® Joins Race to End Prostate Cancer as Official Sponsor of the Great Prostate Cancer Challenge / Dash for Dad
6. Ferring Pharmaceuticals FIRMAGON® Named Official Sponsor of Ed Randalls Bat for the Cure
7. Ferring Pharmaceuticals Announces Disco Icon Gloria Gaynor as National Spokesperson for EUFLEXXA(R)
8. Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
9. Ferring Pharmaceuticals and Gene Security Network Partner to Test Advanced Preimplantation Genetic Diagnosis (PGD) Technology
10. Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics
11. Timm Medical Technologies and Ferring Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Prosed(R) DS
Post Your Comments:
(Date:11/24/2015)... 24, 2015  Thanks to a donor with a ... Medical Center,s Sister Diane Grassilli Center for Women,s Health ... San Francisco . ... forward with a gift of $617,320 that allowed the ... with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) ...
(Date:11/24/2015)... , Nov. 24, 2015  Array BioPharma Inc. ... Chief Executive Officer, Ron Squarer , will ... in New York.  The public is welcome to ... the Array BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  ... December 2, 2015Time:1:30 p.m. Eastern Time Webcast: ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... announced today that the first patient has been enrolled ... a treatment for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States ... Phase 1/2 clinical trial, ESSA intends to demonstrate the ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, ... country to celebrate their sobriety and show through pictures what a positive difference ... photos this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy Products, ... heating products business. Cozy Products explains what this means for business moving forward. , ... the Cozy Products business model: to sell personal heaters that reduce energy consumption, are ...
(Date:11/25/2015)... Livonia, MI (PRWEB) , ... November 25, 2015 , ... ... at Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the ... the medical and surgical intensive care units (totaling 30 beds) from May 2014 through ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... found that regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. ... , She developed the patent-pending RECOVERY BRA for added comfort and support. The ...
(Date:11/25/2015)... ... , ... Since its launch in 2012, the Regenestem brand ... therapies to patients with chronic degenerative medical conditions. Now, the U.S. Patent and ... , Organizations are required to hold a registered trademark in order to make ...
Breaking Medicine News(10 mins):